A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation

Trial Profile

A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Tecarfarin (Primary) ; Warfarin
  • Indications Thromboembolism; Thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TACT
  • Sponsors Armetheon; Espero Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jul 2019.
    • 23 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 30 Mar 2019.
    • 23 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top